TAK
Income statement / Annual
Last year (2024), Takeda Pharmaceutical Company Limited's total revenue was $4.58 T,
an increase of 7.45% from the previous year.
In 2024, Takeda Pharmaceutical Company Limited's net income was $107.93 B.
See Takeda Pharmaceutical Company Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
| Operating Revenue |
$4.58 T |
$4.26 T |
$4.03 T |
$3.57 T |
$3.20 T |
$3.29 T |
$2.10 T |
$1.77 T |
$1.73 T |
$1.81 T |
| Cost of Revenue |
$1.58 T
|
$1.43 T
|
$1.24 T
|
$1.11 T
|
$994.31 B
|
$1.09 T
|
$659.69 B
|
$495.92 B
|
$558.76 B
|
$535.41 B
|
| Gross Profit |
$3.00 T
|
$2.83 T
|
$2.78 T
|
$2.46 T
|
$2.20 T
|
$2.20 T
|
$1.44 T
|
$1.27 T
|
$1.17 T
|
$1.27 T
|
| Gross Profit Ratio |
0.66
|
0.66
|
0.69
|
0.69
|
0.69
|
0.67
|
0.69
|
0.72
|
0.68
|
0.7
|
| Research and Development Expenses |
$730.23 B
|
$729.92 B
|
$633.33 B
|
$526.09 B
|
$455.83 B
|
$492.38 B
|
$368.30 B
|
$325.44 B
|
$312.30 B
|
$345.93 B
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.10 T
|
$1.05 T
|
$997.31 B
|
$886.36 B
|
$875.66 B
|
$964.74 B
|
$717.60 B
|
$628.11 B
|
$619.06 B
|
$650.77 B
|
| Other Expenses |
$823.76 B
|
$834.44 B
|
$662.27 B
|
$588.87 B
|
$362.74 B
|
$643.90 B
|
$908.87 B
|
$707.38 B
|
$705.13 B
|
$795.22 B
|
| Operating Expenses |
$2.66 T
|
$2.62 T
|
$2.29 T
|
$2.00 T
|
$1.69 T
|
$2.10 T
|
$1.28 T
|
$1.03 T
|
$1.02 T
|
$1.14 T
|
| Cost And Expenses |
$4.24 T
|
$4.05 T
|
$3.54 T
|
$3.11 T
|
$2.69 T
|
$3.19 T
|
$1.94 T
|
$1.53 T
|
$1.58 T
|
$1.68 T
|
| Interest Income |
$19.64 B
|
$78.10 M
|
$5.51 B
|
$4.59 B
|
$1.78 B
|
$103.03 M
|
$6.62 B
|
$39.54 B
|
$12.27 B
|
$21.65 B
|
| Interest Expense |
$137.31 B
|
$1.06 B
|
$116.97 B
|
$122.43 B
|
$130.81 B
|
$1.46 B
|
$48.16 B
|
$31.93 B
|
$23.25 B
|
$31.93 B
|
| Depreciation & Amortization |
$761.40 B
|
$644.46 B
|
$664.40 B
|
$583.15 B
|
$559.67 B
|
$583.65 B
|
$247.69 B
|
$182.13 B
|
$171.43 B
|
$197.38 B
|
| EBITDA |
$1.21 T |
$1.14 T |
$1.28 T |
$1.18 T |
$983.72 B |
$671.91 B |
$464.22 B |
$359.96 B |
$296.88 B |
$349.85 B |
| EBITDA Ratio |
0.26
|
0.27
|
0.32
|
0.33
|
0.31
|
0.2
|
0.22
|
0.2
|
0.17
|
0.19
|
| Operating Income Ratio |
0.07
|
0.05
|
0.12
|
0.13
|
0.16
|
0.03
|
0.1
|
0.14
|
0.09
|
0.07
|
| Total Other Income/Expenses Net |
-$167.50 B
|
-$161.28 B
|
-$115.42 B
|
-$158.27 B
|
-$143.03 B
|
-$161.16 B
|
-$110.07 B
|
-$24.58 B
|
-$12.52 B
|
-$10.29 B
|
| Income Before Tax |
$175.08 B
|
$52.79 B
|
$375.09 B
|
$302.57 B
|
$366.24 B
|
-$60.75 B
|
$94.90 B
|
$217.21 B
|
$143.35 B
|
$120.54 B
|
| Income Before Tax Ratio |
0.04
|
0.01
|
0.09
|
0.08
|
0.11
|
-0.02
|
0.05
|
0.12
|
0.08
|
0.07
|
| Income Tax Expense |
$66.94 B
|
-$91.41 B
|
$58.05 B
|
$72.41 B
|
-$9.94 B
|
-$105.04 B
|
-$14.12 B
|
$30.50 B
|
$27.83 B
|
$37.06 B
|
| Net Income |
$107.93 B
|
$144.07 B
|
$317.02 B
|
$230.06 B
|
$376.01 B
|
$44.24 B
|
$109.13 B
|
$186.89 B
|
$114.94 B
|
$80.17 B
|
| Net Income Ratio |
0.02
|
0.03
|
0.08
|
0.06
|
0.12
|
0.01
|
0.05
|
0.11
|
0.07
|
0.04
|
| EPS |
34.17 |
46.05 |
102.15 |
73.57 |
120.36 |
14.21 |
34.78 |
119.68 |
73.58 |
51.13 |
| EPS Diluted |
33.62 |
45.58 |
100.97 |
72.94 |
119.48 |
14.13 |
34.78 |
118.78 |
73.13 |
50.86 |
| Weighted Average Shares Out |
$3.21 B
|
$3.13 B
|
$3.10 B
|
$3.13 B
|
$3.12 B
|
$3.11 B
|
$1.92 B
|
$1.56 B
|
$1.56 B
|
$1.57 B
|
| Weighted Average Shares Out Diluted |
$3.21 B
|
$3.16 B
|
$3.14 B
|
$3.15 B
|
$3.15 B
|
$3.13 B
|
$1.93 B
|
$1.57 B
|
$1.57 B
|
$1.58 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
